Ketosis-Prone Type 2 Diabetes in Patients of Sub-Saharan African Origin
Clinical Pathophysiology and Natural History of β-Cell Dysfunction and Insulin Resistance
- Franck Mauvais-Jarvis1,
- Eugène Sobngwi1,
- Raphaël Porcher2,
- Jean-Pierre Riveline3,
- Jean-Philippe Kevorkian4,
- Christian Vaisse5,
- Guillaume Charpentier3,
- Pierre-Jean Guillausseau4,
- Patrick Vexiau1 and
- Jean-François Gautier1
- 1Department of Endocrinology & Diabetes, Saint-Louis Hospital and University of Paris VII School of Medicine, Paris, France
- 2Department of Medical Biostatistics, Saint-Louis Hospital and University of Paris VII School of Medicine, Paris, France
- 3Department of Diabetes and Metabolic Diseases, Sud Francilien Hospital, Corbeil-Essonnes, France
- 4Department of Internal Medicine B, Lariboisiere Hospital, Paris, France
- 5Diabetes Research Center, Department of Medicine, University of California San Francisco, San Francisco, California
- Address correspondence and reprint requests to Franck Mauvais-Jarvis, MD, Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Baylor College of Medicine, One Baylor Plaza, 520B Houston, TX 77030. E-mail: fmjarvis{at}bcm.tmc.edu
Abstract
Nonautoimmune ketosis-prone diabetic syndromes are increasingly frequent in nonwhite populations. We have characterized a cohort of patients of sub-Saharan African origin who had ketosis-prone type 2 diabetes (n = 111), type 1 diabetes (n = 21), and type 2 diabetes (n = 88) and were admitted to a hospital for management of uncontrolled diabetes. We compared epidemiological, clinical, and metabolic features at diabetes onset and measured insulin secretion (glucagon-stimulated C-peptide) and insulin action (short intravenous insulin tolerance test) during a 10-year follow-up. Ketosis-prone type 2 diabetes shows a strong male predominance, stronger family history, higher age and BMI, and more severe metabolic decompensation than type 1 diabetes. In ketosis-prone type 2 diabetes, discontinuation of insulin therapy with development of remission of insulin dependence is achieved in 76% of patients (non–insulin dependent), whereas only 24% of patients remain insulin dependent. During evolution, ketosis-prone type 2 diabetes exhibit specific β-cell dysfunction features that distinguish it from type 1 and type 2 diabetes. The clinical course of non–insulin-dependent ketosis-prone type 2 diabetes is characterized by ketotic relapses followed or not by a new remission. Progressive hyperglycemia precedes and is a strong risk factor for ketotic relapses (hazard ratio 38). The probability for non–insulin-dependent ketosis-prone type 2 diabetes to relapse is 90% within 10 years, of whom ∼50% will become definitively insulin dependent. Insulin sensitivity is decreased in equal proportion in both ketosis-prone type 2 diabetes and type 2 diabetes, but improves significantly in non–insulin-dependent ketosis-prone type 2 diabetes, only after correction of hyperglycemia. In conclusion, ketosis-prone type 2 diabetes can be distinguished from type 1 diabetes and classical type 2 diabetes by specific features of clinical pathophysiology and also by the natural history of β-cell dysfunction and insulin resistance reflecting a propensity to glucose toxicity.
- DKA, diabetic ketoacidosis
- ICA, islet cell autoantibody
- ITT, insulin tolerance test
- KITT, rate of plasma glucose disappearance
- OHA, oral hypoglycemic agent
Footnotes
-
- Accepted December 1, 2003.
- Received June 8, 2003.
- DIABETES














